DJIA 16,654.77 369.26 2.27%
NASDAQ 4,812.71 115.17 2.45%
S&P 500 1,987.66 47.15 2.43%
market minute promo

company name or ticker

Short Sellers Become More Focused in Major Biotechs

Oversold Conditions For Alexion Pharmaceuticals (ALXN)

Alexion Pharmaceuticals Will Rise Again

Falling Earnings Estimates Signal Weakness Ahead for Alexion Pharmaceuticals (ALXN)

Wall Street Breakfast: Crude Prices Head To The $30s

Omeros' Reveals Positive Data on OMS721 from Phase II

David Swensen Buys Stake in Vanguard MSCI Emerging Markets ETF

Baron Funds Comments on Alexion Pharmaceuticals Inc.

Premarket Biotech Digest: Which Cancer Drug, MannKind's Future, Victoza Trial

This Drugmaker's Incredible Run Looks Far From Done

Alexion Pharmaceuticals has been a biotech investor's dream stock for years and has created a fortune for patient investors. But with a strong product lineup and healthy pipeline, the future looks great, too.
See More Articles...